RepliCel Appoints Brooke Hurford as Corporate Secretary and Director, Finance
Marketwire - Wed Jul 16, 8:00PM CDT
RepliCel Life Sciences Inc. (the "Company"
RepliCel Retains O&M Partners to Coordinate North American Focused Investor Marketing Campaign
Marketwire - Fri Jun 20, 4:00PM CDT
RepliCel Life Sciences Inc. (TSX VENTURE: RP)(OTCQB: REPCF), today announced that it has retained O&M Partners, LLC to assist in targeting non-deal institutional and independent money managers throughout the United States including financial centres often overlooked by biotech companies. This marketing effort will include a combination of group Town Hall conference calls and follow-up roadshows. With the commencement of three human clinical trials before year-end, management is dedicated to meeting as many non-deal investors as possible. This campaign is an integral part of the company's overall marketing effort focused on the United States.
Ubika Research Publishes Research Report on RepliCel Life Sciences Inc. (TSXV: RP)
PR Newswire - Thu Jun 19, 8:59AM CDT
Ubika Research has recently published a new information report on RepliCel Life Sciences Inc. (TSXV: RP) (OTCQB: REPCF), a regenerative medicine company focused on developing autologous cell therapies for multi-billion dollar markets that address diseases caused by a deficit of healthy cells required for normal healing and function, such as chronic tendinosis, damaged skin and pattern baldness.
RepliCel Life Sciences Announces Closing of Third and Final Tranche of Private Placement
Marketwire - Wed Jun 18, 1:29AM CDT
RepliCel Life Sciences Inc. ("RepliCel" or the "Company"
RepliCel Retains Christina Cameron as Canadian Investor Relations Consultant
Marketwire - Thu Jun 05, 4:15PM CDT
RepliCel Life Sciences Inc. (TSX VENTURE: RP)(OTCQB: REPCF), today announced that it has retained Christina Cameron as its Canadian Investor Relations consultant to create and execute the company's investor relations strategy within Canada.
RepliCel Life Sciences' Licensing Partner, Shiseido, Opens Cell Processing and Expansion Facility in Japan to Advance RCH-01, a Treatment for Pattern Baldness
Marketwire - Tue May 20, 7:05AM CDT
RepliCel Life Sciences Inc. (OTCQB: REPCF)(TSX VENTURE: RP) a clinical stage regenerative medicine company focused on the development of autologous cell therapies, is pleased to announce that its RCH-01 licensing partner, Shiseido, celebrated the opening of its new cell-processing facility at the Kobe Biomedical Innovation Cluster (KBIC) located on Port Island, Japan on May 18, 2014. Dignitaries, physicians, partner companies, and government representatives were in attendance at this important event. Shiseido's state-of-the-art facility will focus on the continued research and development, and the commercialization of RepliCel's RCH-01 hair regeneration technology.
RepliCel Reports 2013 Annual Financial Results
Marketwire - Tue Mar 18, 7:04AM CDT
RepliCel Life Sciences Inc. (TSX VENTURE: RP)(OTCQB: REPCF), a clinical stage regenerative medicine company focused on the development of autologous cell therapies, today reported financial results for the year ended December 31, 2013.
RepliCel to Present RCH-01 Phase 1 Clinical Data at the 13th Congress of the Japanese Society for Regenerative Medicine
Marketwire - Thu Feb 27, 7:05AM CST
RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX VENTURE: RP) announced that its Director of Research and Development, Dr. Hisae Nakamura, and its Chief Medical Officer, Dr. Kevin McElwee, will be presenting at the 13th Congress of the Japanese Society for Regenerative Medicine to be held March 4-6, 2014 in Kyoto, Japan. An oral presentation of Phase 1 clinical data for RCH-01 is scheduled for March 5, 2014 between 3-5 p.m. local time.
RepliCel Retains Ubika Communication for Online Capital Market Exposure
Marketwire - Wed Feb 26, 4:01PM CST
RepliCel Life Sciences Inc. (TSX VENTURE: RP)(OTCQB: REPCF), today announced that it has retained Ubika Communication, a division of Ubika Corporation, to provide capital market exposure. Ubika offers capital market exposure services via their flagship website portal smallcapower.com (SCP) which is also featured on the Financial Post website. SCP represents a unique way for small cap companies to bridge between the traditional investor relations business model and the online world that is becoming increasingly important for maximizing shareholder value.
Androgenic Alopecia - Pipeline Review, H2 2013
M2 - Fri Feb 07, 3:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/567n76/androgenic) has announced the addition of the "Androgenic Alopecia - Pipeline Review, H2 2013" report to their offering. This report provides information on the therapeutic development for Androgenic Alopecia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Androgenic Alopecia. Androgenic Alopecia - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for Androgenic Alopecia. - A review of the Androgenic Alopecia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Androgenic Alopecia pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - News and deals relating to the products. Reasons to Buy - Identify and understand important and diverse types of therapeutics under development for Androgenic Alopecia. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Androgenic Alopecia pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Companies Mentioned - Allergan - Histogen - Hygeia Therapeutics - Kasiak Research - Polichem - R-Tech Ueno - RepliCel Life Sciences - SWITCH Biotech - Samumed For more information visit http://www.researchandmarkets.com/research/567n76/androgenic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.
Eurasian Minerals Announces Royalty Interests on Timok Joint Venture Copper-Gold Properties in Serbia
Marketwire - Tue Feb 04, 6:01AM CST
Eurasian Minerals Inc. (TSX VENTURE: EMX)(NYSE MKT: EMXX) (the "Company" or "EMX"
RepliCel Receives Japanese Patent Covering its Hair Regeneration Technology
Marketwire - Mon Jan 13, 7:02AM CST
RepliCel Life Sciences Inc. (TSX VENTURE: RP)(OTCQB: REPCF) today announced that it has been granted a patent by Japan's Ministry of International Trade and Industry for hair follicle mesenchymal stem cells and their use thereof. These cells are used in RepliCel's RCH-01 treatment for androgenetic alopecia, also known as pattern hair loss. With the issuance of this patent, RepliCel now has patents issued in Japan, the United States, Australia and the European Union protecting its technology with other jurisdictions still pending.